Jaguar Health (JAGX) investor relations material

Executive summary

• Special Meeting scheduled for October 23, 2026, to vote on seven key proposals impacting capital structure, compensation, and governance.

• Proposals include share issuances, warrant repricing, stock plan amendments, a reverse stock split, and amendments to financing agreements.

• Board recommends voting in favor of all proposals to enhance flexibility for capital raising and strategic alternatives.

• Forward-looking statements highlight risks related to capital needs, stock price volatility, and Nasdaq listing compliance.

Voting matters and shareholder proposals

• Proposal 1: Approve issuance of common stock upon exchange of Series Q Preferred Stock, potentially diluting current holders.

• Proposal 2: Reprice investor warrants to $1.00 per share, increasing likelihood of exercise and potential dilution.

• Proposal 3: Amend 2014 Stock Incentive Plan to authorize up to 14% of fully diluted shares for equity awards.

• Proposal 4: Authorize a reverse stock split at a ratio between 1-for-2 and 1-for-150, at board discretion.

• Proposal 5: Amend ELOC Agreement to lower the floor price for share sales to C/M Capital, facilitating capital access.

• Proposal 6: Approve issuance of shares to Joshua Mailman and affiliates upon full exercise of warrants, potentially resulting in a change of control.

• Proposal 7: Approve adjournment of the meeting if more time is needed to solicit votes for the above proposals.

Board of directors and corporate governance

• Board retains discretionary authority to set the reverse stock split ratio and timing within approved range.

• Board unanimously recommends approval of all proposals to support strategic flexibility and capital needs.

• Board and compensation committee oversee administration of the 2014 Stock Incentive Plan.